Tag: Dilip Shanghvi
GENERAL Sun Pharma Bets On R&D, Compliance Upgrades To Speed Up Growth Engine

Sun Pharmaceutical Industries is sharpening its focus on research and development, regulatory compliance, and manufacturing capabilities as it targets high single-digit consolidated revenue growth in FY27, Chairman Dilip Shanghvi said during the company’s latest earnings call. The pharmaceutical major continues to invest heavily in strengthening both its global generics and innovative medicines businesses, with R&D […]

CW Bureau · May 30, 2026
GENERAL Sun Pharmaceuticals To Acquire Organon In $11.75-Bn All-Cash Deal

Sun Pharmaceutical Industries Ltd, leading specialty generics company, will acquire Organon at $14 per share in an all-cash transaction, valuing the company at an enterprise value of $11.75 billion, funded through internal accruals and borrowings. The transaction will be executed through a merger of Organon with a subsidiary of Sun Pharma, with Organon surviving the […]

CW Bureau · Apr 27, 2026